MyoKardia Inc. started a proposed underwritten public offering of 3,750,000 common shares.
The South San Francisco, Calif.-based biopharmaceutical company said it intends to grant the underwriters an option to buy an additional 562,500 shares.
MyoKardia plans to use the net proceeds from the offering plus additional cash to fund research and development activities and for working capital and other general corporate purposes.
J.P. Morgan Securities, Bank of America Merrill Lynch, Credit Suisse and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.
